AcelRx Pharmaceuticals (NASDAQ:ACRX) Cut to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRXGet Rating) from a hold rating to a sell rating in a report released on Thursday morning, Zacks.com reports.

According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “

ACRX has been the topic of several other research reports. Cantor Fitzgerald reaffirmed an overweight rating on shares of AcelRx Pharmaceuticals in a research report on Friday, March 11th. HC Wainwright lowered shares of AcelRx Pharmaceuticals from a buy rating to a neutral rating in a research report on Monday, March 14th. Finally, StockNews.com started coverage on shares of AcelRx Pharmaceuticals in a research report on Friday, May 13th. They issued a sell rating on the stock.

Shares of NASDAQ ACRX opened at $0.26 on Thursday. AcelRx Pharmaceuticals has a 1 year low of $0.16 and a 1 year high of $1.67. The stock has a market capitalization of $37.51 million, a P/E ratio of -0.94 and a beta of 0.70. The company has a 50-day moving average price of $0.26 and a 200-day moving average price of $0.44.

AcelRx Pharmaceuticals (NASDAQ:ACRXGet Rating) last released its quarterly earnings results on Monday, May 16th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). During the same quarter in the previous year, the firm earned ($0.08) EPS. On average, research analysts forecast that AcelRx Pharmaceuticals will post -0.22 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Rock Springs Capital Management LP raised its position in shares of AcelRx Pharmaceuticals by 0.8% in the third quarter. Rock Springs Capital Management LP now owns 3,819,402 shares of the specialty pharmaceutical company’s stock valued at $3,896,000 after purchasing an additional 30,645 shares during the period. D. E. Shaw & Co. Inc. grew its stake in AcelRx Pharmaceuticals by 12.3% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 3,721,586 shares of the specialty pharmaceutical company’s stock valued at $2,085,000 after acquiring an additional 407,507 shares in the last quarter. Values First Advisors Inc. grew its stake in AcelRx Pharmaceuticals by 23.7% during the first quarter. Values First Advisors Inc. now owns 642,515 shares of the specialty pharmaceutical company’s stock valued at $183,000 after acquiring an additional 123,241 shares in the last quarter. Millennium Management LLC grew its stake in AcelRx Pharmaceuticals by 40.1% during the fourth quarter. Millennium Management LLC now owns 334,248 shares of the specialty pharmaceutical company’s stock valued at $187,000 after acquiring an additional 95,716 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV purchased a new position in AcelRx Pharmaceuticals during the third quarter valued at approximately $143,000. 23.12% of the stock is currently owned by institutional investors.

AcelRx Pharmaceuticals Company Profile (Get Rating)

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures.

Featured Stories

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.